Ribonate

Ribonate refers to a biological molecule, likely a metabolite, that plays a role in human biochemical pathways. The study of such molecules and their levels within the body is a key aspect of metabolomics, a field dedicated to the comprehensive measurement of endogenous metabolites in biological fluids or cells. Metabolomics provides insights into the physiological state of the human body and how it is influenced by genetic and environmental factors.^[1]

Biological Basis

Genetic variations, particularly single nucleotide polymorphisms (SNPs), can influence the synthesis, metabolism, or transport of various biological molecules, including metabolites. Genome-wide association studies (GWAS) are instrumental in identifying these genetic variants that associate with changes in the homeostasis of such molecules^[1]. ^[2] By analyzing a large number of genetic markers across the entire genome, researchers can pinpoint specific genetic regions or genes that may impact the levels of a given metabolite.

Clinical Relevance

Understanding the genetic underpinnings of metabolite levels, such as ribonate, holds significant clinical relevance. Altered concentrations of metabolites can serve as biomarkers for various health conditions or indicate an increased risk for complex traits. For instance, studies have identified genetic loci associated with biomarkers of cardiovascular disease, such as serum urate and dyslipidemia.^[3]Such research highlights how specific genetic variants can be linked to disease pathways, even if the precise mechanisms are still under investigation.^[3] Metabolomics, in conjunction with genetic studies, acts as a platform for studying gene function and its impact on health. ^[4]

Social Importance

The identification of genetic factors influencing metabolites like ribonate contributes to a broader understanding of human health and disease. This knowledge is crucial for developing personalized medicine approaches, where an individual’s genetic profile could inform disease risk assessment, prevention strategies, and targeted therapeutic interventions. By clarifying the genetic architecture behind various biochemical traits, such research empowers individuals and healthcare providers with more precise tools for maintaining health and managing disease.

Limitations

Methodological and Statistical Considerations

The studies on ribonate acknowledge several methodological and statistical limitations that impact the interpretation of their findings. Many cohorts were of moderate size, which may have limited statistical power to detect associations with modest effect sizes, potentially leading to false negative findings.^[5] Conversely, common to most genome-wide association studies (GWAS), the reported associations could represent false positive findings due to the multiple statistical models and tests performed, with replication in independent cohorts being crucial for validation. ^[5] Some associations, such as specific rs2305198 and rs7072268 variants, were not significant when analyzed individually in linear models, only achieving significance when included in a multiple regression model. ^[6]

Furthermore, the SNP arrays used in some GWAS represent only a subset of all known SNPs in reference databases like HapMap, which means some genes or causal variants may be missed due to incomplete coverage. ^[7] This limitation suggests that a comprehensive understanding of candidate genes might not be achievable with the current GWAS data alone. ^[7] Issues with imputation quality were also noted, with some imputed SNPs having an R-square estimate of 0, indicating low confidence in the imputation for those specific variants. ^[8] Additionally, neglecting to model relatedness among individuals in a sample, where applicable, can lead to misleading P values and inflated false-positive rates, even if some studies did account for polygenic effects. ^[9]

Generalizability and Cohort Specificity

A significant limitation of these studies is the lack of diverse representation in the study populations. The cohorts were predominantly composed of individuals of white European ancestry, often described as largely middle-aged to elderly. ^[5] This demographic specificity means that the generalizability of the findings to younger populations or individuals of other ethnic and racial backgrounds remains uncertain. ^[5] Efforts were made to exclude individuals who did not cluster with the main Caucasian populations based on principal component analysis, reinforcing the focus on specific ancestral groups. ^[10]

Even with methods employed to detect and adjust for population stratification, such as genomic inflation factor and principal component analysis, the possibility of residual substructure within the Caucasian populations cannot be entirely ruled out. ^[8] Such residual stratification could still confound associations, leading to spurious results. Furthermore, the collection of DNA in later examinations of some cohorts may introduce a survival bias, meaning the analyzed population might not be fully representative of the initial study cohort, potentially skewing observed associations. ^[5]

Phenotype Characterization and Unaccounted Factors

The characterization of phenotypes presents its own set of limitations. For instance, echocardiographic traits were sometimes averaged over periods spanning up to twenty years, during which different equipment might have been used, potentially introducing misclassification or variability in measurements. ^[11] This averaging also assumes that genetic and environmental factors influencing traits remain consistent across a wide age range, an assumption that may not hold true, thereby potentially masking age-dependent gene effects. ^[11]

The choice and interpretation of specific biomarkers can also be a source of limitation. For example, using TSH as the sole indicator of thyroid function without measures of free thyroxine or a detailed assessment of thyroid disease could provide an incomplete picture.^[12]Similarly, while cystatin C is a marker for kidney function, it may also reflect cardiovascular disease risk independently, complicating its interpretation.^[12] The studies’ focus on multivariable models might have led to missing important bivariate associations between SNPs and phenotypes, highlighting potential gaps in understanding the full genetic architecture of complex traits. ^[12] Finally, the absence of specific variant information, such as non-SNP variants like those in UGT1A1, can prevent a comprehensive assessment of previously reported associations in the current samples. ^[5]

Variants

Genetic variations within the ENOSF1 gene and in regions influencing the TYMS gene are significant due to their roles in pyrimidine metabolism, DNA synthesis, and cellular proliferation. The TYMSgene encodes thymidylate synthase, a critical enzyme responsible for synthesizing deoxythymidine monophosphate (dTMP), which is an essential building block for DNA replication and repair. TheENOSF1 gene, or Enolase Superfamily Member 1, is known to regulate the expression of TYMS, forming a crucial feedback loop that modulates the availability of nucleotides within cells. ^[1] Specifically, the variant rs2790 , often located in a regulatory region shared by ENOSF1 and TYMS, has been implicated in altering TYMS expression levels, thereby influencing cellular dTMP pools and impacting metabolic processes broadly. ^[13]

Several other variants within the ENOSF1 gene, including rs10502289 , rs2298581 , and rs7239738 , also contribute to this intricate regulatory network. These single nucleotide polymorphisms can affect the transcriptional activity or stability of theENOSF1 gene, subsequently altering its influence on TYMS expression. Such alterations in TYMSlevels can lead to imbalances in nucleotide availability, which are vital for cell division, tissue repair, and overall metabolic homeostasis.^[14] For instance, modified TYMSactivity might impact the efficiency of certain metabolic pathways, potentially influencing the cellular processing of various organic acids, including those derived from sugars like ribonate, by affecting co-factor availability or energy metabolism.^[15]

The cumulative effect of these ENOSF1 and TYMSvariants on nucleotide metabolism can have widespread implications for cellular function and an individual’s metabolic profile. Changes in nucleotide synthesis and DNA repair capacity can indirectly influence processes that impact sugar acid metabolism, such as cellular redox balance and the availability of precursors for complex carbohydrate synthesis. While a direct, explicit link between these variants and ribonate metabolism is complex and often indirect, their fundamental role in DNA metabolism suggests potential broader effects on cellular health and the processing of various biomolecules, including ribonate-related pathways. These variants are therefore key in understanding genetic predispositions to metabolic efficiency and cellular resilience.

Key Variants

RS ID	Gene	Related Traits
rs10502289 rs2298581 rs7239738	ENOSF1	ribonate measurement
rs2790	TYMS, ENOSF1	ribonate measurement urinary metabolite measurement metabolite measurement cerebrospinal fluid composition attribute, xylonate measurement, arabonate measurement

Genetic Regulation of Metabolic Pathways

Genetic variations play a fundamental role in shaping an individual’s metabolic profile by influencing gene function and expression, particularly through mechanisms like alternative splicing. Common single nucleotide polymorphisms (SNPs) within gene regions can significantly alter cellular processes by affecting the pre-mRNA splicing machinery, which in turn leads to the production of diverse protein isoforms with potentially altered activities or stabilities.^[16] These regulatory elements are crucial for the genetic mechanisms that finely tune numerous cellular functions in response to physiological and environmental cues.

A prominent example of this genetic regulation is observed in the 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) gene, where common SNPs are associated with LDL-cholesterol levels and specifically affect the alternative splicing of its exon 13. ^[17] This alternative splicing is a key molecular mechanism that can modify the HMGCRprotein’s structure or degradation rate, thereby influencing the critical mevalonate pathway and overall cholesterol synthesis.^[18] Similarly, the alternative splicing of the APOBmessenger RNA can generate novel isoforms of Apolipoprotein B, demonstrating the extensive regulatory networks by which post-transcriptional modifications contribute to the functional diversity of essential biomolecules in lipid metabolism.^[19]

Lipid and Sterol Metabolism Regulation

The intricate regulation of lipid and sterol metabolism is vital for cellular and systemic health, with 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) serving as the rate-limiting enzyme in the mevalonate pathway, which is indispensable for cholesterol biosynthesis. ^[20] Genetic variations within the HMGCRgene are directly linked to differences in LDL-cholesterol levels, thereby impacting an individual’s overall lipid profile and cardiovascular risk.^[17] The enzyme’s activity is tightly controlled not only by genetic factors but also through its degradation rate and oligomerization state, which collectively modulate its function and represent crucial points for therapeutic intervention. ^[21]

Beyond HMGCR, other key biomolecules significantly influence systemic lipid homeostasis and constitute part of complex signaling pathways. Apolipoprotein C-III (APOC3), for instance, is a critical regulator of triglyceride metabolism, and studies have shown that null mutations inAPOC3 confer a favorable plasma lipid profile and offer apparent cardioprotection. ^[22]Dysregulation of these metabolic processes, often driven by common genetic variants spanning multiple loci, contributes to complex pathophysiological conditions such as polygenic dyslipidemia and an increased risk of coronary artery disease.^[14]

Uric Acid Homeostasis and Renal Transport

The maintenance of uric acid homeostasis is a critical metabolic process, primarily facilitated by the solute carrier family 2 member 9 (SLC2A9), also known as GLUT9, which functions as a newly identified urate transporter.^[23]This essential protein is responsible for regulating serum urate concentrations and facilitating its excretion from the body, predominantly through the kidneys, thus directly influencing systemic urate levels.^[24] Genetic variants within the SLC2A9gene are strongly associated with variations in serum uric acid levels and can exhibit pronounced sex-specific effects, highlighting its significant role in human physiology.^[25]

Disruptions in urate homeostasis can lead to serious pathophysiological conditions, most notably gout, which results from the pathological accumulation of uric acid. Moreover, elevated serum urate levels have broader systemic consequences, including correlations with hypertension and common cardiovascular disease, potentially mediated by mechanisms such as enhanced renin release from the kidney, vasoconstriction, and endothelial dysfunction.^[3]While uric acid is also recognized for its role as an antioxidant defense in humans, its dysregulation underscores a delicate balance in cellular and organ-level biology and the importance of its homeostatic control.^[26]

Systemic Metabolic Interconnections and Pathophysiology

Metabolic processes are not isolated but operate within complex interconnected regulatory networks that are essential for maintaining systemic homeostasis. For example, the enzyme hexokinase 1 (HK1), particularly its red blood cell-specific isozyme, is a key player in glycolysis, and genetic variations in HK1are associated with glycated hemoglobin levels even in non-diabetic populations.^[10] Dysfunctions in red blood cell enzymes involved in glycolysis can broadly impact cellular energy metabolism and oxygen transport, thereby affecting the overall physiological state. ^[27]

Genetic factors also contribute significantly to broader metabolic dysregulation observed in conditions like diabetes and obesity. Genes such as FTO, for instance, are known to influence adiposity, insulin sensitivity, leptin levels, and resting metabolic rate, demonstrating the multifaceted impact of genetic variants on these traits.^[28]Furthermore, polymorphisms in genes encoding hormones like adiponectin and resistin can influence various metabolic phenotypes, illustrating the intricate interplay between adipose tissue, hormonal signaling, and systemic metabolism.^[29]These complex interactions, alongside the influence of genetic variants on plasma levels of liver enzymes and hematological phenotypes, underscore the integrated nature of human health and disease and the systemic consequences of metabolic disruptions.^[30]

Pathways and Mechanisms

Metabolic Regulation and Flux Control

Metabolic pathways are central to maintaining homeostasis, involving intricate networks of biosynthesis, catabolism, and energy metabolism that are tightly regulated to control molecular flux. For instance, the mevalonate pathway, catalyzed in part by HMGCR (3-hydroxy-3-methylglutaryl coenzyme A reductase), is a critical biosynthetic route for cholesterol, and its regulation significantly influences plasma lipid concentrations. ^[31] Genetic variations in genes like APOC3 can lead to altered lipid profiles, demonstrating a direct link between genetic factors and metabolic outcomes. ^[22]Similarly, the balance of uric acid levels is maintained through the action of transporters such asSLC2A9 (GLUT9) and SLC22A12, which regulate the excretion and reabsorption of urate, thus controlling its metabolic flux.^[32] Furthermore, energy metabolism pathways, including glycolysis, are influenced by enzymes like HK1(hexokinase 1), which is associated with glycated hemoglobin levels and plays a role in red blood cell function.^[10]

Cellular Signaling and Transcriptional Dynamics

Cellular signaling cascades and transcriptional regulation are fundamental mechanisms that govern gene expression and cellular responses. Genetic variants, such as single nucleotide polymorphisms (SNPs), can profoundly influence these processes, for example, by affecting alternative splicing patterns. Common SNPs inHMGCR have been shown to alter the alternative splicing of exon 13, subsequently impacting LDL-cholesterol levels, indicating a regulatory mechanism at the pre-mRNA processing stage that dictates protein function and abundance. ^[31]Beyond splicing, overall gene regulation of metabolic enzymes and transporters, like those involved in lipid or urate metabolism, is crucial. The expression levels of genes such asSLC2A9are tightly controlled, with variations influencing the capacity for urate transport and ultimately contributing to individual differences in serum uric acid concentrations.^[1]

Post-Translational Control and Allosteric Modulation

Beyond genetic and transcriptional control, proteins are subject to various post-translational modifications and allosteric regulation, which rapidly modulate their activity, localization, and stability. The degradation rate of HMGCR, for instance, is influenced by its oligomerization state, highlighting a mechanism that controls enzyme abundance and, consequently, the rate of cholesterol biosynthesis. ^[18] Proteins involved in ubiquitination, such as the RING-H2 finger ubiquitin ligase PJA1, represent another layer of post-translational control, targeting proteins for degradation and thus regulating their half-life and cellular concentration. ^[33] While specific examples of allosteric control were not detailed, the general principles of protein modification allow for rapid adjustments to metabolic pathway activity in response to cellular signals or substrate availability, ensuring dynamic regulation of enzyme function.

Inter-pathway Crosstalk and Systems Integration

Biological systems operate through highly integrated networks where various pathways constantly interact, demonstrating significant crosstalk and emergent properties. Metabolomics studies reveal a complex interplay between genetic variants and a broad spectrum of metabolite profiles, indicating that changes in one metabolic pathway can have ripple effects across the entire metabolome.^[1]For example, multiple genetic loci contribute to conditions like polygenic dyslipidemia, where the combined effect of variants in different genes—rather than a single gene—orchestrates the overall lipid profile and disease risk.^[14] Furthermore, signaling molecules, such as the neuronal chemorepellent Slit2, can inhibit vascular smooth muscle cell migration by suppressing Rac1 activation, illustrating how signaling pathways can crosstalk to influence diverse cellular processes like vascular function.^[34] This complex network interaction underscores the hierarchical regulation and emergent properties that define physiological states.

Dysregulation and Disease Mechanisms

Dysregulation of metabolic and signaling pathways is a direct cause of many diseases, and understanding these mechanisms is critical for identifying therapeutic targets. For instance, dyslipidemia, characterized by abnormal lipid concentrations, is influenced by newly identified genetic loci and is a significant risk factor for coronary artery disease.^[9] Pathogenic mutations in genes like APOC3 can lead to favorable plasma lipid profiles and confer apparent cardioprotection, suggesting that modulating APOC3activity could be a therapeutic strategy for cardiovascular health.^[22]Similarly, dysregulation of urate transporters, specificallySLC2A9, is directly implicated in altered serum urate concentrations and the development of gout, providing a clear pathway for potential pharmacological intervention.^[23]Cardiac conditions, such as hypertrophy, also involve changes in gene expression and can result from channelopathies in proteins like the cardiac ryanodine receptor (hRyR2), illustrating how specific molecular dysfunctions translate into clinical disease.^[35]

Clinical Relevance

Prognostic Value and Risk Stratification

Biomarkers play a crucial role in predicting disease outcomes and stratifying individuals by risk for various conditions. For instance, circulating inflammatory markers like C-reactive protein (CRP) are established predictors of incident stroke, coronary heart disease, and all-cause mortality, underscoring their prognostic significance in cardiovascular disease.^[5]Similarly, the level of kidney function serves as a significant risk factor for atherosclerotic cardiovascular outcomes and mortality, even in elderly populations.^[12] Identifying genetic variants, such as those in HNF1Aassociated with CRP levels, could contribute to early risk stratification, allowing for personalized preventive strategies before the onset of symptomatic disease.^[36]This predictive capacity is essential for guiding clinical decisions, from lifestyle interventions to pharmacotherapy, aiming to improve long-term patient health.

Diagnostic Utility and Treatment Selection

The diagnostic utility of biomarkers extends beyond mere disease detection, informing risk assessment and enabling tailored treatment approaches. Genetic associations with traits like serum uric acid, involving genes such asGLUT9, highlight a potential avenue for identifying individuals at risk for conditions like gout and hyperuricemia.^[32] Understanding the genetic underpinnings of biomarker variability, for example, the influence of SNPs on LDL-cholesterol levels involving genes like HMGCR, can refine risk assessment for dyslipidemia and cardiovascular disease.^[31] Such insights can guide the selection of appropriate therapeutic interventions, potentially including targeted statin therapy or other lipid-lowering agents, based on an individual’s genetic profile and biomarker status.

Associations with Comorbidities and Monitoring

Biomarkers often exhibit associations with multiple comorbidities, reflecting complex physiological interplays and overlapping disease phenotypes. Elevated uric acid levels, for example, have been linked to hypertension and cardiovascular disease, although the precise mechanistic links, such as enhanced renin release or nitric oxide suppression, require further elucidation.^[3]Monitoring strategies informed by biomarker levels are vital for tracking disease progression and assessing treatment efficacy. For instance, the reproducibility of biomarkers like CRP and other inflammatory markers allows for consistent assessment of systemic inflammation over time, which is critical given their role in various chronic conditions.^[5] This comprehensive understanding of biomarker associations and their dynamic changes can inform management strategies, helping to mitigate complications and improve outcomes in patients with complex health profiles.

References

[1] Gieger C et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.” PLoS Genet, 2008.

[2] McCarthy, Mark I., et al. “Genome-wide association studies for complex traits: consensus, uncertainty and challenges.” Nature Reviews Genetics, vol. 9, no. 5, 2008, pp. 356–369.

[3] Wallace, C, Newhouse SJ, Buchanan D, Caulfield MJ, Farrall M, et al. “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.” Am J Hum Genet, 2008.

[4] Nicholson, Jeremy K., et al. “Metabonomics: a platform for studying drug toxicity and gene function.” Nature Reviews Drug Discovery, vol. 1, no. 2, 2002, pp. 153–161.

[5] Benjamin, E. J. et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Med Genet, vol. 8 Suppl 1, 2007, pp. S11.

[6] Pare, G. et al. “Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study.”PLoS Genet, vol. 5, no. 1, 2009, pp. e1000322.

[7] Yang, Q, Liu Y, Lougee EC, Vasan RS, Chen MH, et al. “Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.” BMC Med Genet, 2007.

[8] Dehghan, A. et al. “Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study.”Lancet, vol. 372, no. 9654, 2008, pp. 1953-1961.

[9] Willer, C. J. et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”Nat Genet, vol. 40, no. 2, 2008, pp. 161-169.

[10] Pare, G, Havel PJ, Bailey SD, Mondry A, Montpetit A, et al. “Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women’s Genome Health Study.” PLoS Genet, 2008.

[11] Vasan, R. S. et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Med Genet, vol. 8 Suppl 1, 2007, pp. S2.

[12] Hwang, S. J. et al. “A genome-wide association for kidney function and endocrine-related traits in the NHLBI’s Framingham Heart Study.” BMC Med Genet, vol. 8 Suppl 1, 2007, pp. S10.

[13] Saxena R et al. “Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.” Science, 2007.

[14] Kathiresan S et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet, 2008.

[15] Melzer D et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genet, 2008.

[16] Johnson, JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD, Santos R, Schadt EE, Stoughton R, Shoemaker DD. “Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays.” Science, 2003.

[17] Burkhardt, R. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, 2008.

[18] Cheng, HH, Xu L, Kumagai H, Simoni RD. “Oligomerization state influences the degradation rate of 3-hydroxy-3-methylglutaryl-CoA reductase.” J Biol Chem, 1999.

[19] Khoo, B, Roca X, Chew SL, Krainer AR. “Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.” BMC Mol Biol, 2007.

[20] Goldstein, JL, Brown MS. “Regulation of the mevalonate pathway.” Nature, 1990.

[21] Istvan, ES, Palnitkar M, Buchanan SK, Deisenhofer J. “Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis.” Embo J, 2000.

[22] Pollin, TI, Damcott CM, Shen H, Ott SH, Shuldiner AR, et al. “A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.” Science, 2008.

[23] Vitart, V, Rudan I, Hayward C, Kolcic V, Fornage D, et al. “SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout.” Nat Genet, 2008.

[24] Enomoto, A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, et al. “Molecular identification of a renal urate anion exchanger that regulates blood urate levels.” Nature, 2002.

[25] Doring, A, Gieger C, Mehta D, Gohlke H, Prokisch H, et al. “SLC2A9 influences uric acid concentrations with pronounced sex-specific effects.” Nat Genet, 2008.

[26] Ames, BN, Cathcart R, Schwiers E, Hochstein P. “Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.” Proc Natl Acad Sci U S A, 1981.

[27] van Wijk, R, van Solinge WW. “The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis.” Blood, 2005.

[28] Do, R, Bailey SD, Desbiens K, Belisle A, Montpetit A, et al. “Genetic variants of FTO influence adiposity, insulin sensitivity, leptin levels, and resting metabolic rate in the Quebec Family Study.” Diabetes, 2008.

[29] Krizova, J, Dolinkova M, Lacinova Z, Sulek S, Dolezalova R, et al. “Adiponectin and resistin gene polymorphisms in patients with anorexia nervosa and obesity and its influence on metabolic phenotype.” Physiol Res, 2007.

[30] Yuan, X, Waterworth D, Glorioso N, Muggia M, Pilia MG, et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” Am J Hum Genet, 2008.

[31] Burkhardt, R. et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol, 2009.

[32] Li, S, Sanna S, Maschio A, Busonero F, Usala G, et al. “The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts.” PLoS Genet, 2007.

[33] Yu, P. et al. “PJA1, encoding a RING-H2 finger ubiquitin ligase, is a novel human X chromosome gene abundantly expressed in brain.” Genomics, 2002.

[34] Liu, D. et al. “Neuronal chemorepellent Slit2 inhibits vascular smooth muscle cell migration by suppressing small GTPase Rac1 activation.”Circ Res, 2006.

[35] Haugen, E. et al. “Parallel gene expressions of IL-6 and BNP during cardiac hypertro-phy complicated with diastolic dysfunction in spontaneously hypertensive rats.” Int J Cardiol, 2006.

[36] Reiner, A. P., et al. “Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein.”American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1199-1205.